IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.11
+0.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 109.2M | 6.6M | 2.2M | 5.2M |
| Cost of Revenue | 25.5M | 13.1M | — | — | — |
| Gross Profit | (25.5M) | 96.1M | 6.6M | 2.2M | 5.2M |
| Operating Expenses | |||||
| R&D Expense | 75.9M | 95.7M | 107.2M | 92.7M | 97.2M |
| SG&A Expense | 20.2M | 24.0M | 33.2M | 34.7M | 31.9M |
| General & Admin Expense | 20.2M | 24.0M | 33.2M | 34.7M | 31.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.8M) | (8.6M) | 4.3M | 21.4M | 10.0M |
| Total Operating Expenses | 93.3M | 111.1M | 144.7M | 148.8M | 139.0M |
| Cost and Expenses | 118.8M | 124.2M | 144.7M | 148.8M | 139.0M |
| Operating Income (EBIT) | (118.8M) | (15.0M) | (138.1M) | (146.5M) | (133.8M) |
| Non-Operating | |||||
| Interest Income | 6.9M | 7.3M | 13.0M | 12.7M | 3.0M |
| Interest Expense | — | — | — | 540.0K | — |
| Net Interest Income | 6.9M | 7.3M | 13.0M | 12.1M | 3.0M |
| Other Non-Op Income/Expense | 8.9M | 5.4M | 13.4M | 11.8M | 3.0M |
| Non-Operating Income (excl Interest) | (14.0M) | (5.4M) | (13.4M) | (12.3M) | (4.2M) |
| EBT (Pre-Tax Income) | (109.9M) | (9.6M) | (124.8M) | (134.8M) | (130.8M) |
| Income Tax Expense | (68.0K) | (68.0K) | 1.8M | 1.9M | 91.0K |
| Bottom Line | |||||
| Net Income | (109.8M) | (9.6M) | (126.6M) | (136.7M) | (130.9M) |
| Earnings from Cont. Ops | (109.8M) | (9.6M) | (126.6M) | (136.7M) | (130.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (109.8M) | (9.6M) | (126.6M) | (136.7M) | (130.9M) |
| Per Share | |||||
| Basic EPS | ($1.04) | ($0.11) | ($1.61) | ($2.30) | ($2.27) |
| Diluted EPS | ($1.04) | ($0.11) | ($1.61) | ($2.30) | ($2.27) |
| Revenue Per Share | $0.00 | $1.26 | $0.08 | $0.04 | $0.09 |
| Shares | |||||
| Basic Shares Outstanding | 205.8M | 86.6M | 78.6M | 59.3M | 57.8M |
| Diluted Shares Outstanding | 205.8M | 86.6M | 78.6M | 59.3M | 57.8M |
| Profitability Metrics | |||||
| EBITDA | (95.1M) | 3.5M | (111.5M) | (121.2M) | (121.2M) |
| D&A | 9.7M | 13.1M | 13.3M | 13.0M | 8.4M |
| EBIT | (104.8M) | (9.6M) | (124.8M) | (134.3M) | (129.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026